Cell No. : Cell Name
RCB2323 : 9-15C
update : 2023/10/16
|
| Comment | Mouse mesenchymal cell line derived from bone marrow. C3H/He |
| Comment from the depositor | |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Umezawa, Akihiro
|
| Originator |
Umezawa, Akihiro
|
| Year of deposit |
2006
|
| Animal |
_mouse
< Mammals
|
| Strain name |
C3H/He
|
| Tissue |
bone marrow
|
| Classification |
normal
|
|
Lifespan |
infinite
|
| Morphology |
fibroblast-like
|
| Cellosaurus(Expasy) |
CVCL_6532
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Adherent cells
|
| Culture medium |
|
POWEREDBY10
|
| Antibiotics |
|
Free
|
|
Passage method |
|
0.25% Trypsin
|
Culture information
|
Passage cell No |
|
2-3 x 10 5 cells/100 mm dish
|
| SC frequency |
|
Subculture : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma/Acholeplasma |
|
(-)
|
| SSLP(mouse) |
|
OK
|
| Isozyme |
|
LD, NP
|
| Images |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
2
|
| User's Publication |
4
|
| Reference |
|
8027
Toyoda M, Yamazaki-Inoue M, Itakura Y, Kuno A, Ogawa T, Yamada M, Akutsu H, Takahashi Y, Kanzaki S, Narimatsu H, Hirabayashi J, Umezawa A.
Lectin microarray analysis of pluripotent and multipotent stem cells.
Genes Cells
2011
16:1-11
PubMed ID: 21155951
DOI: 10.1111/j.1365-2443.2010.01459.x
|
|
6508
Yamada Y, Sakurada K, Takeda Y, Gojo S, Umezawa A.
Single-cell-derived mesenchymal stem cells overexpressing Csx/Nkx2.5 and GATA4 undergo the stochastic cardiomyogenic fate and behave like transient amplifying cells.
Exp Cell Res
2007
313(4):698-706
PubMed ID: 17208226
DOI: 10.1016/j.yexcr.2006.11.012
|
| User's Publication |
|
18232
Smith AL, Eiken AP, Skupa SA, Moore DY, Umeta LT, Smith LM, Lyden ER, D'Angelo CR, Kallam A, Vose JM, Kutateladze TG, El-Gamal D.
A Novel Triple-Action Inhibitor Targeting B-Cell Receptor Signaling and BRD4 Demonstrates Preclinical Activity in Chronic Lymphocytic Leukemia
Int J Mol Sci
2022
23(12):6712
PubMed ID: 35743155
DOI: 10.3390/ijms23126712
|
|
18181
El-Gamal D, Williams K, LaFollette TD, Cannon M, Blachly JS, Zhong Y, Woyach JA, Williams E, Awan FT, Jones J, Andritsos L, Maddocks K, Wu CH, Chen CS, Lehman A, Zhang X, Lapalombella R, Byrd JC.
PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL
Blood
2014
124(9):1481-91
PubMed ID: 25001469
DOI: 10.1182/blood-2014-05-574830
|
|
15661
Fiorcari S, Brown WS, McIntyre BW, Estrov Z, Maffei R, O'Brien S, Sivina M, Hoellenriegel J, Wierda WG, Keating MJ, Ding W, Kay NE, Lannutti BJ, Marasca R, Burger JA.
The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells
PLoS One
2013
8(12):e83830
PubMed ID: 24376763
DOI: 10.1371/journal.pone.0083830
|
|
7732
Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, Giese N, O'Brien S, Yu A, Miller LL, Lannutti BJ, Burger JA.
The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.
Blood
2011
118:3603-12
PubMed ID: 21803855
DOI: 10.1182/blood-2011-05-352492
|
Back
Top
CELL BANK Website
